3Q4C
Crystal Structure of Wild Type BRAF kinase domain in complex with organometallic inhibitor CNS292
Summary for 3Q4C
Entry DOI | 10.2210/pdb3q4c/pdb |
Descriptor | Serine/threonine-protein kinase B-raf, [(1,2,3,4,5,6-eta)-(1S,2R,3R,4R,5S,6S)-1-carboxycyclohexane-1,2,3,4,5,6-hexayl](chloro)(3-methyl-5,7-dioxo-6,7-dihydro-5H-pyrido[2,3-a]pyrrolo[3,4-c]carbazol-12-ide-kappa~2~N~1~,N~12~)ruthenium(1+) (2 entities in total) |
Functional Keywords | kinase, inhibitor, oncoprotein, melanoma, kinase-kinase inhibitor complex, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
Biological source | Homo sapiens (human) |
Cellular location | Nucleus (By similarity): P15056 |
Total number of polymer chains | 2 |
Total formula weight | 70994.20 |
Authors | Xie, P.,Streu, C.,Qin, J.,Pregman, H.,Pagano, N.,Meggers, E.,Marmorstein, R. (deposition date: 2010-12-23, release date: 2011-03-02, Last modification date: 2024-02-21) |
Primary citation | Xie, P.,Streu, C.,Qin, J.,Bregman, H.,Pagano, N.,Meggers, E.,Marmorstein, R. The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase. Biochemistry, 48:5187-5198, 2009 Cited by PubMed: 19371126DOI: 10.1021/bi802067u PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (3.2 Å) |
Structure validation
Download full validation report